News

Boosting regenerative medicine
Enlarge image

FundingUKGermanySpainNetherlands

Boosting regenerative medicine

30.05.2012 - Regenerative medicine centres foster their translational approach. An international initiative formed in Germany, a new centre is opened in Scotland.

Edinburgh/Enschede/Seville/Berlin/Toronto – The Scottish Centre for Regenerative Medicine (SCRM) officially started operations on May 28. The SCRM will conduct cutting-edge stem cell research to find new therapies for Multiple Sclerosis, Parkinson’s disease, motor neuron disease and heart and liver disease. Up to 250 scientists will work at the centre, which is funded by the University of Edinburgh, the Medical Research Council, Scottish Enterprise and the British Heart Foundation with up to £54m. The SCRM will put an special emphasis on translational efforts, turning laboratory discoveries faster into treatments. An additional newly founded £24m bioincubator, named „Nine, Edinburgh Bioquarter“ offers lab and office space to start-up ventures and established biotech companies.

Just days before, the Regenerative Medicine Coalition constituted itself in Germany’s capital city Berlin. Six translational medicine centres from Europe and North America joined forces to push stem cell based medicine forward. The Berlin-Brandenburg Centre for Regenerative Therapies (BRCT, Berlin, Germany), the Centre for Commercialisation of Regenerative Medicine (Toronto, Canada), the MIRA Institute for Biomedical Technology and Technical Medicine (Enschede, The Netherlands), the Andalusian Molecular Biology and Regenerative Medicine Centre (Seville, Spain), the McGowan Institute of Regenerative Medicine (Pittsburgh, USA) and the Institute for Regenerative Medicine (Winston Salem, USA) are among the founding members. „We plan to jointly tackle projects in order to accelerate the development of therapies”, announced Frank Lauter from BRCT.

http://www.european-biotechnology-news.com/news/news/2012-02/boosting-regenerative-medicine.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

M&ASwitzerland

04.05.2015 Swiss crop chemical maker Syngenta AG is in talks with US company Monsanto to discuss a possible merger, insiders say.

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BASILEA133.60 CHF4.70%
  • WILEX4.20 EUR3.45%
  • STRATEC BIOMEDICAL48.52 EUR3.23%

FLOP

  • MEDIGENE8.58 EUR-4.88%
  • PAION2.51 EUR-4.56%
  • CYTOS0.63 CHF-3.08%

TOP

  • 4SC4.65 EUR257.7%
  • SYNGENTA422.00 CHF28.3%
  • SARTORIUS169.65 EUR18.6%

FLOP

  • CYTOS0.63 CHF-37.6%
  • MEDIGENE8.58 EUR-33.2%
  • CO.DON2.89 EUR-8.3%

TOP

  • WILEX4.20 EUR418.5%
  • FORMYCON27.70 EUR316.5%
  • 4SC4.65 EUR315.2%

FLOP

  • MOLOGEN4.92 EUR-53.7%
  • BIOFRONTERA2.30 EUR-28.6%
  • PAION2.51 EUR-22.8%

No liability assumed, Date: 25.05.2015